A recent meta-analysis that will be published soon in JACC Intv offers evidence of benefit derived from short-term dual antiplatelet therapy for elderly patients. This is a patient group that has always been excluded from the major trials, while remaining one of the most challenging subgroups in which to balance bleeding and ischemic risks. The<a href="https://solaci.org/en/2018/03/27/dual-antiplatelet-therapy-less-is-more-for-elderly-patients/" title="Read more" >...</a>
The DAPT study concluded that continued thienopyridine plus aspirin beyond a year after coronary angioplasty is associated with a decrease in the rate of stent thrombosis and major cardiovascular events. In contrast, there is a significant increase in moderate to severe bleeding when compared with continued aspirin alone. Based on the outcomes of this and<a href="https://solaci.org/en/2017/11/21/angioplasty-complexity-may-define-the-duration-of-dual-antiplatelet-therapy/" title="Read more" >...</a>
Original Title: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Reference: Levine GN et al. Circulation. 2016 Mar 29. [Epub ahead of print]. Courtesy of Dr. Alejandro Lakowsky. The new ACC-AHAGuidelines on the optimal duration of dual antiplatelet therapy(DAPT) in patients with coronary artery disease have just been<a href="https://solaci.org/en/2016/04/01/optimal-duration-of-dual-antiplatelet-therapy-new-acc-aha-guidelines/" title="Read more" >...</a>
Original title: Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. Reference: Marco Valgimigli et al. J Am Coll Cardiol. 2015;65(8):805-815. The use of drug eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been studied prospectively. Data on patients at high risk of bleeding and low restenosis are limited. This study compared<a href="https://solaci.org/en/2015/02/25/n-5027/" title="Read more" >...</a>
Original title: Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month – Dual Antiplatelet Therapy- The SECURITY Randomized Clinical Trial. Reference: Antonio Colombo et al. J Am CollCardiol. 2014 Nov 18;64(20):2086-97. The optimal duration of dual antiplatelet therapy after second-generation DES implantation is still debated and apparently will remain controversial for some time. The aim of this<a href="https://solaci.org/en/2015/01/15/n-4908/" title="Read more" >...</a>
Reference: Kandzari DE, Barrer CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011; 4: 1119-28.2011; 4: 1119-28. Patients treated with zotarolimus-eluting stents (ZES) suffer no excess late ischemic events if they take dual antiplatelet therapy for 6 months instead of 12 months or longer,<a href="https://solaci.org/en/2011/11/29/n-4005/" title="Read more" >...</a>
Percutaneous left atrial appendage occlusion (LAAO) has surged as an effective alternative to treat patients with atrial fibrillation (AF) presenting counterindications for oral anticoagulants. However, the optimal antithrombotic treatment after LAAO is still debated, seeing as it should prevent device related thrombosis (DRT) while minimizing bleeding risk. The aim of this retrospective study carried out<a href="https://solaci.org/en/2024/05/01/single-antiplatelet-therapy-following-percutaneous-left-atrial-appendage-occlusion/" title="Read more" >...</a>
Short dual antiplatelet therapy (DAPT) has shown benefits in patients receiving drug eluting stents (DES), reducing bleeding with no concomitant increase in major adverse cardiovascular events (MACE). Traditionally, the therapeutic window was limited to monotherapy with P2Y12 inhibitors during the first year and there are few data on short DAPT followed by long term monotherapy<a href="https://solaci.org/en/2024/01/29/clopidogrel-monotherapy-beyond-12-months-long-term-analysis-of-the-stopdapt-2/" title="Read more" >...</a>
An increasing number of patients currently present both an elevated ischemic risk and hemorrhagic risk. This means that the selection of the optimal antiplatelet treatment is a clinical challenge. Several studies have shown that P2Y12 monotherapy after minimum dual antiplatelet therapy (DAPT) is a novel strategy to reduce bleeding risk without increasing ischemic risk. Furthermore,<a href="https://solaci.org/en/2023/08/30/esc-2023-extended-monotherapy-with-clopidogrel-vs-dapt-in-high-risk-patients/" title="Read more" >...</a>
Dual antiplatelet therapy (DAPT) is the current standard for preventing thrombotic events in high-risk patients with coronary artery disease, as well as in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). However, this approach increases the risk of bleeding. To reduce this risk, there have been studies that discontinued the use of<a href="https://solaci.org/en/2023/08/29/mact-study-monotherapy-with-p2y12-inhibitor-associated-with-colchicine-after-acute-coronary-syndrome/" title="Read more" >...</a>